Inequity in Access to Transcatheter Aortic Valve Replacement: A Pan-Canadian Evaluation of Wait-Times.


Journal

The Canadian journal of cardiology
ISSN: 1916-7075
Titre abrégé: Can J Cardiol
Pays: England
ID NLM: 8510280

Informations de publication

Date de publication:
06 2020
Historique:
received: 11 07 2019
revised: 13 10 2019
accepted: 21 10 2019
pubmed: 1 5 2020
medline: 17 2 2021
entrez: 1 5 2020
Statut: ppublish

Résumé

There has been an exponential increase in the demand for transcatheter aortic valve replacement (TAVR). Our goal was to examine trends in TAVR capacity and wait-times across Canada. All TAVR cases were identified from April 1, 2014, to March 31, 2017. Wait-time was defined as the duration in days from the initial referral to the TAVR procedure. TAVR capacity was defined as the number of TAVR procedures per million population/province/fiscal year. We performed multivariable multilevel Cox proportional hazards modelling of the time to TAVR as the dependant variable and the effect of provinces as random effects. We quantified the variation in wait-times among provinces using the median hazard ratio. We identified a total of 4906 TAVR procedures across 9 provinces. Despite a year over year increase in overall capacity, there was a greater than 3-fold difference in capacity between provinces. Crude median wait-times increased over time in all provinces, with marked variation from 71.5 days in Newfoundland to 190.5 and 203 days in Manitoba and Alberta, respectively. This suggests increasing demand outpaced the growth in capacity. We found a median hazard ratio of 1.62, indicating that in half of the possible pairwise comparisons, the time to TAVR for identical patients was at least 62% longer between different provinces. We found substantial geographic inequity in TAVR access. This calls for policy makers, clinicians, and administrators across Canada to address this inequity through revaluation of provincial funding mechanisms, as well as implementation of efficient care pathways.

Sections du résumé

BACKGROUND
There has been an exponential increase in the demand for transcatheter aortic valve replacement (TAVR). Our goal was to examine trends in TAVR capacity and wait-times across Canada.
METHODS
All TAVR cases were identified from April 1, 2014, to March 31, 2017. Wait-time was defined as the duration in days from the initial referral to the TAVR procedure. TAVR capacity was defined as the number of TAVR procedures per million population/province/fiscal year. We performed multivariable multilevel Cox proportional hazards modelling of the time to TAVR as the dependant variable and the effect of provinces as random effects. We quantified the variation in wait-times among provinces using the median hazard ratio.
RESULTS
We identified a total of 4906 TAVR procedures across 9 provinces. Despite a year over year increase in overall capacity, there was a greater than 3-fold difference in capacity between provinces. Crude median wait-times increased over time in all provinces, with marked variation from 71.5 days in Newfoundland to 190.5 and 203 days in Manitoba and Alberta, respectively. This suggests increasing demand outpaced the growth in capacity. We found a median hazard ratio of 1.62, indicating that in half of the possible pairwise comparisons, the time to TAVR for identical patients was at least 62% longer between different provinces.
CONCLUSION
We found substantial geographic inequity in TAVR access. This calls for policy makers, clinicians, and administrators across Canada to address this inequity through revaluation of provincial funding mechanisms, as well as implementation of efficient care pathways.

Identifiants

pubmed: 32349882
pii: S0828-282X(19)31353-4
doi: 10.1016/j.cjca.2019.10.018
pii:
doi:

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

844-851

Commentaires et corrections

Type : CommentIn

Informations de copyright

Copyright © 2019 Canadian Cardiovascular Society. Published by Elsevier Inc. All rights reserved.

Auteurs

Harindra C Wijeysundera (HC)

Schulich Heart Centre, Divisions of Cardiology and Cardiac Surgery, Sunnybrook Health Sciences Centre, University of Toronto, Toronto, Ontario, Canada; Institute for Clinical Evaluative Sciences, Toronto, Ontario, Canada; Institute for Health Policy Management and Evaluation, University of Toronto, Toronto, Ontario, Canada. Electronic address: harindra.wijeysundera@sunnybrook.ca.

Kayley A Henning (KA)

Institute for Clinical Evaluative Sciences, Toronto, Ontario, Canada.

Feng Qiu (F)

Institute for Clinical Evaluative Sciences, Toronto, Ontario, Canada.

Corey Adams (C)

Division of Cardiothoracic Surgery, Health Science Centre, Memorial University of Newfoundland, St John's, Newfoundland, Canada.

Faisal Al Qoofi (F)

Libin Cardiovascular Institute of Alberta, Division of Cardiology, Foothills Hospital, University of Calgary, Calgary, Alberta, Canada.

Anita Asgar (A)

Montréal Heart Institute, Division of Cardiology, University of Montréal, Montréal, Quebec, Canada.

Peter Austin (P)

Institute for Clinical Evaluative Sciences, Toronto, Ontario, Canada; Institute for Health Policy Management and Evaluation, University of Toronto, Toronto, Ontario, Canada; Schulich Heart Research Program, Sunnybrook Research Institute, University of Toronto, Toronto, Ontario, Canada.

Kevin R Bainey (KR)

Mazankowski Alberta Heart Institute, Division of Cardiology, University of Alberta Hospital, University of Alberta, Edmonton, Alberta, Canada.

Eric A Cohen (EA)

Schulich Heart Centre, Divisions of Cardiology and Cardiac Surgery, Sunnybrook Health Sciences Centre, University of Toronto, Toronto, Ontario, Canada.

Benoit Daneault (B)

Division of Cardiology, Sherbrooke University, Sherbrooke, Québec, Canada.

Stephen Fremes (S)

Schulich Heart Centre, Divisions of Cardiology and Cardiac Surgery, Sunnybrook Health Sciences Centre, University of Toronto, Toronto, Ontario, Canada.

Malek Kass (M)

Division of Cardiology, St Boniface General Hospital, University of Manitoba, Winnipeg, Manitoba, Canada.

Dennis T Ko (DT)

Schulich Heart Centre, Divisions of Cardiology and Cardiac Surgery, Sunnybrook Health Sciences Centre, University of Toronto, Toronto, Ontario, Canada; Institute for Clinical Evaluative Sciences, Toronto, Ontario, Canada; Institute for Health Policy Management and Evaluation, University of Toronto, Toronto, Ontario, Canada.

Laurie Lambert (L)

Cardiovascular Evaluation Unit, INESS, Québec City, Québec, Canada.

Sandra B Lauck (SB)

Centre for Heart Valve Innovation, St Paul's Hospital, University of British Columbia, Vancouver, British Columbia, Canada.

Kendra MacFarlane (K)

Canadian Cardiovascular Society, Ottawa, Ontario, Canada.

Syed Najaf Nadeem (SN)

Division of Cardiology, Queen Elizabeth II Health Sciences Centre, Dalhousie University, Halifax, Nova Scotia, Canada.

Garth Oakes (G)

CorHealth Ontario, Toronto, Ontario, Canada.

Vernon Paddock (V)

Division of Cardiology, Saint John Regional Hospital, Dalhousie University, Halifax, Nova Scotia, Canada.

Marc Pelletier (M)

Division of Cardiac Surgery, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts.

Mark Peterson (M)

Division of Cardiac Surgery, St Michael's Hospital, University of Toronto, Toronto, Ontario, Canada.

Nicolo Piazza (N)

Division of Cardiology, McGill University Health Centre, McGill University, Montréal, Québec, Canada.

Brian J Potter (BJ)

Division of Cardiology, University of Montréal Hospital Centre, University of Montréal, Montréal, Québec, Canada.

Sam Radhakrishnan (S)

Schulich Heart Centre, Divisions of Cardiology and Cardiac Surgery, Sunnybrook Health Sciences Centre, University of Toronto, Toronto, Ontario, Canada.

Josep Rodes-Cabau (J)

Québec Heart and Lung Institute, Laval University, Québec City, Canada.

Olga Toleva (O)

Division of Cardiology, St Boniface General Hospital, University of Manitoba, Winnipeg, Manitoba, Canada.

John G Webb (JG)

Centre for Heart Valve Innovation, St Paul's Hospital, University of British Columbia, Vancouver, British Columbia, Canada.

Robert Welsh (R)

Mazankowski Alberta Heart Institute, Division of Cardiology, University of Alberta Hospital, University of Alberta, Edmonton, Alberta, Canada.

David Wood (D)

Division of Cardiology, Vancouver General Hospital, University of British Columbia, Vancouver, British Columbia; Vancouver Coastal Health Research Institute, Vancouver, British Columbia, Canada.

Graham Woodward (G)

CorHealth Ontario, Toronto, Ontario, Canada.

Rodney Zimmermann (R)

Division of Cardiology, Regina Qu'Appelle Health District, University of Saskatchewan, Regina, Saskatchewan, Canada.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH